COMMUNIQUÉS West-GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
02/07/2024
Aggregated presentation by day and by market Purchases of own shares from June 24th to 28th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024
02/07/2024
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 24 au 28 juin 2024 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
02/07/2024
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 2 juillet 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Canadian Red Cross and Walmart Canada launch annual giving campaign
02/07/2024
Funds raised in support of building stronger and more resilient communities OTTAWA, July 02, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross, in collaboration with Walmart Canada, is proud to announce the start of its [...]
La Croix-Rouge canadienne et Walmart Canada lancent leur campagne annuelle de dons
02/07/2024
Des fonds amassés pour créer des collectivités plus fortes et plus résilientes OTTAWA, 02 juill. 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne, en collaboration avec Walmart Canada, est fière d’annoncer le [...]
Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialist
02/07/2024
On June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023. Founded in [...]
Virbac finalise l’acquisition des parts minoritaires de Globion, spécialiste indien des vaccins volaille
02/07/2024
Virbac finalise l’acquisition des parts minoritaires de Globion, spécialiste indien des vaccins volaille Le 21 juin, nous avons finalisé l'acquisition des parts minoritaires de Globion, portant ainsi notre participation [...]
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02/07/2024
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic [...]
QIAGEN N.V. to release results for Q2 2024 and hold webcast
02/07/2024
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, [...]
Biogen Completes Acquisition of Human Immunology Biosciences
02/07/2024
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on [...]
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
02/07/2024
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice Compared to controls, [...]
Myriad Genetics Earns 2024 Great Place To Work® Certification™
02/07/2024
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the [...]
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
02/07/2024
The ceremony will be held in celebration of Scilex’s launch of GLOPERBA ® , an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July [...]
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
02/07/2024
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- [...]
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02/07/2024
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia ® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia [...]
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02/07/2024
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia [...]
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
02/07/2024
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two Patients at Optimal Dose, [...]
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
02/07/2024
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Vaxcyte Appoints John Furey to Board of Directors
02/07/2024
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today [...]

Pages